— Aldosterone synthase inhibitor baxdrostat indicated as add-on to other antihypertensives
May 18, 2026
• 2 min read
The FDA approved the first-in-class oral aldosterone synthase inhibitor baxdrostat (Baxfendy) to treat adults with uncontrolled hypertension in combination with other antihypertensive drugs, AstraZeneca announced.
Aldosterone can raise blood pressure by stimulating retention of sodium and water and is a key contributor to persistently uncontrolled hypertension. Baxdrostat has high selectivity for aldosterone synthase, suppressing hormone synthesis rather than blocking the mineralocorticoid receptor and reducing off-target effects.
